Jan Marek Slominski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jan Marek Slominski has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Ewa Jassem
Department of Pulmonology, Medical University of Gdansk, Smoluchowskiego 17, 80-214 Gdańsk, Poland
11 shared publications L Wolska-Goszka
10 shared publications- Alicja Siemińska
Department of Allergology and Pneumonology, Medical University of Gdańsk, Gdańsk, Poland
7 shared publications - Anna Dubaniewicz
Department of Pulmonology, Medical University of Gdansk, Poland
7 shared publications E Jassem
7 shared publications- Krzysztof Kuziemski
Department of Pulmonology, School of Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 78 Jagiellońska Street, 10-357 Olsztyn, Poland
5 shared publications
Latest Publications
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA1947
The utility of transthoracic lung ultrasound in assessing pulmonary sarcoidosis
Background: A transthoracic lung ultrasound (TLUS) is noninvasive and nonradiative diagnostic exam, used to assess structures within lungs and mediastinal lymph nodes. Although it is not commonly used in diagnostic and monitoring of sarcoidosis (SA) activity Objective: Attempt to assess the utility of TLUS in diagnostic and monitoring SA activity Methods: We evaluated TLUS in 88 patients with SA (I-IV stages), using linear and convex probe. Right (R) and left (L) lung were divided into 5 fields: ANTERIOR -upper (RA1, LA1) and lower (RA2, LA2), POSTERIOR -upper (RP1, LP1) and lower (RP2, LP2), and AXILLARY (AR, AL). Ultrasound findings were assessed as abnormal: lymph nodes (in long axis >10mm), irregular pleural line, multiple (≥ 6) B lines, consolidations and fluid in pleural cavity. Correlation between HRCT and TLUS was assessed. In group of 21 patients conducted monitoring of SA activity Results: During TLUS examination irregular pleural lines occurred in all fields, but most frequent in RP2 (in 42%), small consolidations (5mm) most frequent in RA1 (13%). B line artefacts ≥ 6 occurred most frequently in RA1 and RA2 (4%). A fluid in pleural cavity occurred most frequent in LP2 (17%). According to HR-CT scan, TLUS revealed lymph nodes: paratracheal (33%), in upper mediastinum (57%). TLUS revealed progression of sarcoidosis in 11 patients and in 4 patients regression of SA Conclusion: According to HRCT, TLUS revealed subpleural findings and lymph nodes of upper mediastinum. Most of abnormal findings were in anterior-lower fields of RL. TLUS seems to be useful in monitoring of SA activity. Study founded by grant (ST-02-0127/07/232)
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA1947
The utility of transthoracic lung ultrasound in assessing pulmonary sarcoidosis
Background: A transthoracic lung ultrasound (TLUS) is noninvasive and nonradiative diagnostic exam, used to assess structures within lungs and mediastinal lymph nodes. Although it is not commonly used in diagnostic and monitoring of sarcoidosis (SA) activity Objective: Attempt to assess the utility of TLUS in diagnostic and monitoring SA activity Methods: We evaluated TLUS in 88 patients with SA (I-IV stages), using linear and convex probe. Right (R) and left (L) lung were divided into 5 fields: ANTERIOR -upper (RA1, LA1) and lower (RA2, LA2), POSTERIOR -upper (RP1, LP1) and lower (RP2, LP2), and AXILLARY (AR, AL). Ultrasound findings were assessed as abnormal: lymph nodes (in long axis >10mm), irregular pleural line, multiple (≥ 6) B lines, consolidations and fluid in pleural cavity. Correlation between HRCT and TLUS was assessed. In group of 21 patients conducted monitoring of SA activity Results: During TLUS examination irregular pleural lines occurred in all fields, but most frequent in RP2 (in 42%), small consolidations (5mm) most frequent in RA1 (13%). B line artefacts ≥ 6 occurred most frequently in RA1 and RA2 (4%). A fluid in pleural cavity occurred most frequent in LP2 (17%). According to HR-CT scan, TLUS revealed lymph nodes: paratracheal (33%), in upper mediastinum (57%). TLUS revealed progression of sarcoidosis in 11 patients and in 4 patients regression of SA Conclusion: According to HRCT, TLUS revealed subpleural findings and lymph nodes of upper mediastinum. Most of abnormal findings were in anterior-lower fields of RL. TLUS seems to be useful in monitoring of SA activity. Study founded by grant (ST-02-0127/07/232)
- 1 September 2017
- Published by European Respiratory Society (ERS)
- Vol. 50 (suppl 61) , PA3261
Malondialdehyde and nitrotyrosine as markers of peroxynitrite activity in sarcoidosis
Sarcoidosis (SA) is granulomatous disease with unknown etiology. Infectious factors, genetics and autoimmunity are considered in the etiopathogenesis of SA. In contrast to tuberculosis (TB), we evidenced decreased clearance of immune complexes with mycobacterial heat shock proteins by resistant to apoptosis monocytes with diminished serum microbicidal/degradable nitrate⁄nitrite and increased concentration of peroxynitrite (ONOO-) in SA. ONOO- reacts with a variety of lipids and proteins initiating peroxidation process with subsequent oxidative tissue injury. Malondialdehyde (MDA) and nitrotyrosine (NT) are the final products of peroxynitrite formation. MDA is product of polyunsaturated fatty acids peroxidation in cells, whereas NT represents a specific peroxynitrite-mediated protein modification. The alterations may generate or mask antigenic epitopes and stimulate relevant T- and/or B-cells, leading to a breakdown or bypass of tolerance, e.g. in SA. Therefore in the same tested group, we evaluated serum levels of MDA and NT in 20 SA patients, 19 TB patients and 21 healthy volunteers using ELISA method. Our study revealed higher concentration of MDA and NT in TB and SA than in controls (p<0.001, p<0.001, respectively) but levels of these final products were higher in SA than TB (p<0.001, p<0.001, respectively). Increased levels of MDA and NT in our patients with SA than in TB highlight greater an imbalance between oxidants and antioxidants in the etiopathogenesis of sarcoidosis. Additionally, overproduction of malondialdehyde and nitrotyrosine, the peroxynitrite-driven nitration of biomolecules may lead to an autoimmune response, considered in sarcoidosis. Grant:ST-02-0127/07/232.
- 1 September 2017
- Published by European Respiratory Society (ERS)
- Vol. 50 (suppl 61) , PA3261
Malondialdehyde and nitrotyrosine as markers of peroxynitrite activity in sarcoidosis
Sarcoidosis (SA) is granulomatous disease with unknown etiology. Infectious factors, genetics and autoimmunity are considered in the etiopathogenesis of SA. In contrast to tuberculosis (TB), we evidenced decreased clearance of immune complexes with mycobacterial heat shock proteins by resistant to apoptosis monocytes with diminished serum microbicidal/degradable nitrate⁄nitrite and increased concentration of peroxynitrite (ONOO-) in SA. ONOO- reacts with a variety of lipids and proteins initiating peroxidation process with subsequent oxidative tissue injury. Malondialdehyde (MDA) and nitrotyrosine (NT) are the final products of peroxynitrite formation. MDA is product of polyunsaturated fatty acids peroxidation in cells, whereas NT represents a specific peroxynitrite-mediated protein modification. The alterations may generate or mask antigenic epitopes and stimulate relevant T- and/or B-cells, leading to a breakdown or bypass of tolerance, e.g. in SA. Therefore in the same tested group, we evaluated serum levels of MDA and NT in 20 SA patients, 19 TB patients and 21 healthy volunteers using ELISA method. Our study revealed higher concentration of MDA and NT in TB and SA than in controls (p<0.001, p<0.001, respectively) but levels of these final products were higher in SA than TB (p<0.001, p<0.001, respectively). Increased levels of MDA and NT in our patients with SA than in TB highlight greater an imbalance between oxidants and antioxidants in the etiopathogenesis of sarcoidosis. Additionally, overproduction of malondialdehyde and nitrotyrosine, the peroxynitrite-driven nitration of biomolecules may lead to an autoimmune response, considered in sarcoidosis. Grant:ST-02-0127/07/232.
- Open Access
- 4 May 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0177194
Copy number variation of FCGR genes in etiopathogenesis of sarcoidosis
We have previously revealed that, in contrast to polymorphism of FCGR2B and FCGR3B, polymorphism of FCGR2A, FCGR2C and FCGR3A genes, encoding receptors for Fc fragment of immunoglobulin G (Fcγ receptors), play a role in increased level of circulating immune complexes with occurrence of Mycobacterium tuberculosis heat shock proteins in patients with sarcoidosis. However, this immunocomplexemia might also be caused by decreased clearance by immune cells due to a changed copy number of FCGR genes. Thus, the next step of our study was to evaluate copy number variation of FCGR2A, FCGR2B, FCGR2C, FCGR3A and FCGR3B in this disease. The analysis was carried out by real-time quantitative PCR on 104 patients and 110 healthy volunteers. Despite previously detected variation in allele/genotype frequencies of FCGR in sarcoidosis and its particular stages, there was no copy number variation of the tested genes between sarcoidosis or its stages and healthy control, as well as between stages themselves. A relevant increase in copy number of FCGR2C and FCGR3B in Stage IV of sarcoidosis vs. other stages and controls was detected, but this observation was based on a limited number of Stage IV patients. Hence, polymorphism of FCGR genes seems to be more important than their copy number variation in etiopathogenesis of sarcoidosis in patients from the Polish population.
- 4 May 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0177194
Open AccessCopy number variation of FCGR genes in etiopathogenesis of sarcoidosis
We have previously revealed that, in contrast to polymorphism of FCGR2B and FCGR3B, polymorphism of FCGR2A, FCGR2C and FCGR3A genes, encoding receptors for Fc fragment of immunoglobulin G (Fcγ receptors), play a role in increased level of circulating immune complexes with occurrence of Mycobacterium tuberculosis heat shock proteins in patients with sarcoidosis. However, this immunocomplexemia might also be caused by decreased clearance by immune cells due to a changed copy number of FCGR genes. Thus, the next step of our study was to evaluate copy number variation of FCGR2A, FCGR2B, FCGR2C, FCGR3A and FCGR3B in this disease. The analysis was carried out by real-time quantitative PCR on 104 patients and 110 healthy volunteers. Despite previously detected variation in allele/genotype frequencies of FCGR in sarcoidosis and its particular stages, there was no copy number variation of the tested genes between sarcoidosis or its stages and healthy control, as well as between stages themselves. A relevant increase in copy number of FCGR2C and FCGR3B in Stage IV of sarcoidosis vs. other stages and controls was detected, but this observation was based on a limited number of Stage IV patients. Hence, polymorphism of FCGR genes seems to be more important than their copy number variation in etiopathogenesis of sarcoidosis in patients from the Polish population.
- 1 September 2016
- Published by European Respiratory Society (ERS)
- Vol. 48 (suppl 60) , PA829
Polymorphism and copy number variation ofFCGRgenes in an etiopathogenesis of sarcoidosis
Background: The immunocomplexemia in our patients with Stage I/II of sarcoidosis (SA), not with Stage III/IV, may be a result of phagocytes' disorder of abilities in clearance of immune complexes (CIs), which rely on the function of receptors for Fc fragment of IgG (FcγR). However, we revealed increased FcγRs' expression on phagocytes in the same SA patients. It may point to a lowered affinity of FcγRs to CIs due to a polymorphism and/or copy number variation (CNV) of FCGR genes, encoding FcγRs. Aim/Materials/Methods: Thus, we analyzed polymorphism and CNV of FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCGR3B genes in 124 SA patients and 148 healthy volunteers (C) using PCR-SSP and Real-Time PCR. Results: We revealed significantly lower percentage of FCGR2A and FCGR2C with more functional variants of these genes in Stages I/II vs. III/IV of SA. Moreover, the V158F polymorphism of FCGR3A , responsible for a decreased affinity of FcγRIIIa to CIs and their decreased clearance was increased in Stage I vs. Stage II and C. There was no aberration in FCGR2B and FCGR3B variants, as well in CNV of tested genes between SA or its stages and C, as well as between stages themselves. We only detected a relevant increase in CNV of FCGR2C and FCGR3B in Stage IV of SA vs. other stages and C, but a broader study is needed to verify this. Conclusions: Thus, FCGR2A, FCGR2C and FCGR3A polymorphism may contribute to immunocomplexemia present in SA. The assessment of FCGR genes could become a tool in presaging a clinical course of SA and in its personalized therapy. CNV of FCGR genes seems to be less important than FCGR polymorphism in the etiopathogenesis of SA in our patients. Support by grants: 5160/B/P01/2010/39 and 02-0127/07/232.
- 1 September 2016
- Published by European Respiratory Society (ERS)
- Vol. 48 (suppl 60) , PA829
Polymorphism and copy number variation ofFCGRgenes in an etiopathogenesis of sarcoidosis
Background: The immunocomplexemia in our patients with Stage I/II of sarcoidosis (SA), not with Stage III/IV, may be a result of phagocytes' disorder of abilities in clearance of immune complexes (CIs), which rely on the function of receptors for Fc fragment of IgG (FcγR). However, we revealed increased FcγRs' expression on phagocytes in the same SA patients. It may point to a lowered affinity of FcγRs to CIs due to a polymorphism and/or copy number variation (CNV) of FCGR genes, encoding FcγRs. Aim/Materials/Methods: Thus, we analyzed polymorphism and CNV of FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCGR3B genes in 124 SA patients and 148 healthy volunteers (C) using PCR-SSP and Real-Time PCR. Results: We revealed significantly lower percentage of FCGR2A and FCGR2C with more functional variants of these genes in Stages I/II vs. III/IV of SA. Moreover, the V158F polymorphism of FCGR3A , responsible for a decreased affinity of FcγRIIIa to CIs and their decreased clearance was increased in Stage I vs. Stage II and C. There was no aberration in FCGR2B and FCGR3B variants, as well in CNV of tested genes between SA or its stages and C, as well as between stages themselves. We only detected a relevant increase in CNV of FCGR2C and FCGR3B in Stage IV of SA vs. other stages and C, but a broader study is needed to verify this. Conclusions: Thus, FCGR2A, FCGR2C and FCGR3A polymorphism may contribute to immunocomplexemia present in SA. The assessment of FCGR genes could become a tool in presaging a clinical course of SA and in its personalized therapy. CNV of FCGR genes seems to be less important than FCGR polymorphism in the etiopathogenesis of SA in our patients. Support by grants: 5160/B/P01/2010/39 and 02-0127/07/232.
- Open Access
- 10 March 2015
- Published by VM Media Group sp. z o.o in Advances in Respiratory Medicine
- Vol. 83 (2) , 135-139
Tracheobronchopathia Osteochondroplastica—Case Report and Literature Review
Tracheobronchopathia osteochondroplastica (TBO) is a rare disease of unknown etiology characterised by a formation of multiple, cartilaginous and osteocartilaginous submucosal nodules in the trachea and major bronchi. The course of the disease is usually benign but the narrowing of the respiratory tract can lead to chronic non-specific clinical symptoms. We present a case of a 50-year old man with chronic exertional dyspnoea and stenosis of the trachea visible in imaging tests, in whom the symptoms were caused by TBO.
- 10 March 2015
- Published by VM Media Group sp. z o.o in Advances in Respiratory Medicine
- Vol. 83 (2) , 135-139
Open AccessTracheobronchopathia Osteochondroplastica—Case Report and Literature Review
Tracheobronchopathia osteochondroplastica (TBO) is a rare disease of unknown etiology characterised by a formation of multiple, cartilaginous and osteocartilaginous submucosal nodules in the trachea and major bronchi. The course of the disease is usually benign but the narrowing of the respiratory tract can lead to chronic non-specific clinical symptoms. We present a case of a 50-year old man with chronic exertional dyspnoea and stenosis of the trachea visible in imaging tests, in whom the symptoms were caused by TBO.
- Open Access
- 12 January 2015
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 125 (1-2) , 46-53
Risk factors for anaphylaxis in patients with mastocytosis
Symptoms resulting from the activation and release of mediators from the mast cells are observed in about 30% of the patients with mastocytosis. The aim of the study was to assess the prevalence of anaphylactic reactions and to identify the risk factors for anaphylaxis in patients with mastocytosis depending on the type of the disease. Furthermore, we analyzed a response to treatment of mediator-related symptoms in this patient group. The study group included 152 adult patients with mastocytosis. The diagnostic workup included a histopathological examination, flow cytometry, KIT mutation analysis, and measurement of tryptase levels. The diagnosis of allergy was confirmed by the skin prick test and serum immunoglobulin E levels. The prevalence of anaphylactic reactions in the study group was 50% and was higher in patients with systemic mastocytosis (P = 0.007), specifically in its indolent variant (P = 0.026), than in patients with cutaneous mastocytosis. The most frequent triggers of anaphylaxis were food (29%), insect stings (22%), and drugs (15%). Tryptase levels were higher in patients with a history of anaphylaxis (P = 0.029) as well as in those with symptoms provoked by physical factors (P = 0.002). Such symptoms were reported in 112 patients (74%) and were more common in patients with systemic mastocytosis compared with those with cutaneous mastocytosis (P = 0.026). The treatment was ineffective in 8 patients (10.5%) and resulted only in partial remission in 14 patients (18.4%). The study showed a significant incidence of symptoms related to physical factors in patients with mastocytosis and anaphylaxis in history. Risk factors for anaphylaxis included increased serum tryptase levels and indolent variant of systemic mastocytosis. Standard pharmacological treatment was ineffective in 10% of the patients, who may require biological treatment.
- 12 January 2015
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 125 (1-2) , 46-53
Open AccessRisk factors for anaphylaxis in patients with mastocytosis
Symptoms resulting from the activation and release of mediators from the mast cells are observed in about 30% of the patients with mastocytosis. The aim of the study was to assess the prevalence of anaphylactic reactions and to identify the risk factors for anaphylaxis in patients with mastocytosis depending on the type of the disease. Furthermore, we analyzed a response to treatment of mediator-related symptoms in this patient group. The study group included 152 adult patients with mastocytosis. The diagnostic workup included a histopathological examination, flow cytometry, KIT mutation analysis, and measurement of tryptase levels. The diagnosis of allergy was confirmed by the skin prick test and serum immunoglobulin E levels. The prevalence of anaphylactic reactions in the study group was 50% and was higher in patients with systemic mastocytosis (P = 0.007), specifically in its indolent variant (P = 0.026), than in patients with cutaneous mastocytosis. The most frequent triggers of anaphylaxis were food (29%), insect stings (22%), and drugs (15%). Tryptase levels were higher in patients with a history of anaphylaxis (P = 0.029) as well as in those with symptoms provoked by physical factors (P = 0.002). Such symptoms were reported in 112 patients (74%) and were more common in patients with systemic mastocytosis compared with those with cutaneous mastocytosis (P = 0.026). The treatment was ineffective in 8 patients (10.5%) and resulted only in partial remission in 14 patients (18.4%). The study showed a significant incidence of symptoms related to physical factors in patients with mastocytosis and anaphylaxis in history. Risk factors for anaphylaxis included increased serum tryptase levels and indolent variant of systemic mastocytosis. Standard pharmacological treatment was ineffective in 10% of the patients, who may require biological treatment.
- 1 January 2015
- Published by Springer Nature
- Vol. 905, 57-68
Polymorphism of FCGR2A, FCGR2C, and FCGR3B Genes in the Pathogenesis of Sarcoidosis
We have previously presented evidence that the polymorphism of the FCGR3A gene, encoding the receptor for Fc fragment of immunoglobulin G IIIa (FcγRIIIa) plays a role in the enhancement of circulating immune complexes (CIs) with the occurrence of Mycobacterium tuberculosis heat shock proteins in patients with sarcoidosis (SA). The immunocomplexemia might be caused by decreased affinity of CIs to Fcγ receptors, with the subsequently decreased receptor clearance by immune cells. In the present study we examined whether the polymorphisms of other related genes (FCGR2A, FCGR2C, FCGR3B) encoding other activatory Fcγ receptors, could have a similar effect. To this end, we genotyped 124 patients with sarcoidosis and 148 healthy volunteers using polymerase chain reaction with sequence-specific primers. We revealed a significant decrease in the percentage of the FCGR2A and FCGR2C variants that ensure effective CIs clearance, with a concomitant increase of less functional variants of these genes in Stages I/II, compared with Stages III/IV of SA. There was no aberration in FCGR3B allele/genotype frequencies. We conclude that the FCGR2A and FCGR2C polymorphisms may also contribute to immunocomplexemia present in SA. The assessment of FCGR genes could become a tool in presaging a clinical course of sarcoidosis and in its personalized therapy.
- 1 January 2015
- Published by Springer Nature
- Vol. 905, 57-68
Polymorphism of FCGR2A, FCGR2C, and FCGR3B Genes in the Pathogenesis of Sarcoidosis
We have previously presented evidence that the polymorphism of the FCGR3A gene, encoding the receptor for Fc fragment of immunoglobulin G IIIa (FcγRIIIa) plays a role in the enhancement of circulating immune complexes (CIs) with the occurrence of Mycobacterium tuberculosis heat shock proteins in patients with sarcoidosis (SA). The immunocomplexemia might be caused by decreased affinity of CIs to Fcγ receptors, with the subsequently decreased receptor clearance by immune cells. In the present study we examined whether the polymorphisms of other related genes (FCGR2A, FCGR2C, FCGR3B) encoding other activatory Fcγ receptors, could have a similar effect. To this end, we genotyped 124 patients with sarcoidosis and 148 healthy volunteers using polymerase chain reaction with sequence-specific primers. We revealed a significant decrease in the percentage of the FCGR2A and FCGR2C variants that ensure effective CIs clearance, with a concomitant increase of less functional variants of these genes in Stages I/II, compared with Stages III/IV of SA. There was no aberration in FCGR3B allele/genotype frequencies. We conclude that the FCGR2A and FCGR2C polymorphisms may also contribute to immunocomplexemia present in SA. The assessment of FCGR genes could become a tool in presaging a clinical course of sarcoidosis and in its personalized therapy.
- Open Access
- 25 February 2014
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 82 (2) , 96-104
Factors Influencing Adherence to Treatment in COPD Patients and Its Relationship with Disease Exacerbations
Introduction: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in the world. Systematic treatment of COPD decreases symptoms and reduces the frequency of exacerbations and hospitalisations because of the disease. It is estimated that only 50% of patients use prescribed drugs systematically. The aim of this study was to identify the factors which can influence adherence to treatment of the patients who were treated due to exacerbation of COPD. Material and Methods: A questionnaire probe was conducted on 49 patients hospitalised at the Regional Lung and Tuberculosis Hospital in Olsztyn, Poland due to COPD exacerbation. The assessed variables were: quality of life and adherence to treatment 30 days after discharge from hospital in relationship with demographic factors, social status, disease and hospitalisation course, and relief after systematic treatment. Results: Most of the patients assessed their health condition as poor and the disease as limiting their everyday social and occupational activity. 30 days after discharge from hospital the adherence rate to therapy was only 67%. There was an association between systematic treatment and the rate of exacerbations (p = 0.045) and hospitalisations (p = 0.005) but also clinical benefit after long-term treatment (p = 0.023). There were no associations between adherence to treatment and sex, place of residence, education or occupation. Conclusions: Lack of systematic treatment is the main risk factor for COPD exacerbations and hospitalisation rate. A subjective sense of relief after drugs is a factor improving patients’ compliance.
- 25 February 2014
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 82 (2) , 96-104
Open AccessFactors Influencing Adherence to Treatment in COPD Patients and Its Relationship with Disease Exacerbations
Introduction: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in the world. Systematic treatment of COPD decreases symptoms and reduces the frequency of exacerbations and hospitalisations because of the disease. It is estimated that only 50% of patients use prescribed drugs systematically. The aim of this study was to identify the factors which can influence adherence to treatment of the patients who were treated due to exacerbation of COPD. Material and Methods: A questionnaire probe was conducted on 49 patients hospitalised at the Regional Lung and Tuberculosis Hospital in Olsztyn, Poland due to COPD exacerbation. The assessed variables were: quality of life and adherence to treatment 30 days after discharge from hospital in relationship with demographic factors, social status, disease and hospitalisation course, and relief after systematic treatment. Results: Most of the patients assessed their health condition as poor and the disease as limiting their everyday social and occupational activity. 30 days after discharge from hospital the adherence rate to therapy was only 67%. There was an association between systematic treatment and the rate of exacerbations (p = 0.045) and hospitalisations (p = 0.005) but also clinical benefit after long-term treatment (p = 0.023). There were no associations between adherence to treatment and sex, place of residence, education or occupation. Conclusions: Lack of systematic treatment is the main risk factor for COPD exacerbations and hospitalisation rate. A subjective sense of relief after drugs is a factor improving patients’ compliance.
- 17 December 2013
- Vol. 30 (4) , 317-20
Transthoracic lung ultrasonography in pulmonary alveolar proteinosis - case report.
A pulmonary alveolar proteinosis (PAP) is a rare disease characterized by an accumulation of surfactant components in lung alveoli. In diagnosis and monitoring of the disease high resolution computed tomography (HRCT) is usually used. Unfortunately, repeated exposure to CT scanning may be associated with an increased risk of radiation. We present a patient in whom repeated transthoracic lung ultrasonography (TLUS) brought parallel to HRCT data in assessing PAP extent. It may indicate that TLUS might be potentially a relevant tool in monitoring of PAP.
- 17 December 2013
- Vol. 30 (4) , 317-20
Transthoracic lung ultrasonography in pulmonary alveolar proteinosis - case report.
A pulmonary alveolar proteinosis (PAP) is a rare disease characterized by an accumulation of surfactant components in lung alveoli. In diagnosis and monitoring of the disease high resolution computed tomography (HRCT) is usually used. Unfortunately, repeated exposure to CT scanning may be associated with an increased risk of radiation. We present a patient in whom repeated transthoracic lung ultrasonography (TLUS) brought parallel to HRCT data in assessing PAP extent. It may indicate that TLUS might be potentially a relevant tool in monitoring of PAP.
- Open Access
- 14 May 2013
- Published by Springer Nature in Lung
- Vol. 191 (4) , 397-404
Intima-Media Thickness in Patients With Obstructive Sleep Apnea Without Comorbidities
Background Obstructive sleep apnea (OSA) is associated with elevated risk of cardiovascular events. The early stages of vascular complications can be visualized by means of ultrasound. Intima-media thickness (IMT) correlates with the presence of risk factors of cardiovascular diseases such as hypertension, diabetes, tobacco smoking, or hyperlipidemia. However, little is known whether OSA itself may be the cause of IMT thickening. Methods The study group was composed of 28 patients (6 women, 22 men; mean age = 53.8 years, mean BMI = 27.1 kg/m2, mean AHI = 22.4/h) with OSA who had no comorbidities. The control group consisted of 28 healthy subjects (6 women, 22 men; mean age = 53.9 years; mean BMI = 27.5 kg/m2). In both groups IMT was assessed in common carotid arteries with the use of ultrasonography. Additionally, in patients with OSA, pulse wave velocity, echocardiography, 24-h automated blood pressure monitoring, clinical signs and symptoms, and blood tests were performed to investigate possible correlations with IMT. Results Median IMT was 0.41 mm in OSA patients and 0.46 mm in the control group (p = 0.087). Echocardiography revealed left ventricle hypertrophy in 21 %, systolic disorders in 8 %, and diastolic disorders in 57 % of the patients. In a large majority of patients, pulse wave velocity was found to be normal. IMT correlated with age (r = 0.446, p = 0.017), total cholesterol (r = 0.518, p = 0.005), daytime systolic blood pressure (r = 0.422, p = 0.025), pulse pressure 24 h and daytime (r = 0.424, p = 0.027 and r = 0.449, p = 0.019), early mitral flow/atrial mitral flow (E/A) (r = −0.429, p = 0.023), and posterior wall diameter (PWD) (r = 0.417, p = 0.270). Conclusion In a relatively nonobese group of patients, no significant differences were found in the intima-media thickness between OSA patients without concomitant cardiovascular diseases and healthy controls. This may lead to the conclusion that IMT does not reflect increased risk of cardiovascular events in patients with isolated OSA.
- 14 May 2013
- Published by Springer Nature in Lung
- Vol. 191 (4) , 397-404
Open AccessIntima-Media Thickness in Patients With Obstructive Sleep Apnea Without Comorbidities
Background Obstructive sleep apnea (OSA) is associated with elevated risk of cardiovascular events. The early stages of vascular complications can be visualized by means of ultrasound. Intima-media thickness (IMT) correlates with the presence of risk factors of cardiovascular diseases such as hypertension, diabetes, tobacco smoking, or hyperlipidemia. However, little is known whether OSA itself may be the cause of IMT thickening. Methods The study group was composed of 28 patients (6 women, 22 men; mean age = 53.8 years, mean BMI = 27.1 kg/m2, mean AHI = 22.4/h) with OSA who had no comorbidities. The control group consisted of 28 healthy subjects (6 women, 22 men; mean age = 53.9 years; mean BMI = 27.5 kg/m2). In both groups IMT was assessed in common carotid arteries with the use of ultrasonography. Additionally, in patients with OSA, pulse wave velocity, echocardiography, 24-h automated blood pressure monitoring, clinical signs and symptoms, and blood tests were performed to investigate possible correlations with IMT. Results Median IMT was 0.41 mm in OSA patients and 0.46 mm in the control group (p = 0.087). Echocardiography revealed left ventricle hypertrophy in 21 %, systolic disorders in 8 %, and diastolic disorders in 57 % of the patients. In a large majority of patients, pulse wave velocity was found to be normal. IMT correlated with age (r = 0.446, p = 0.017), total cholesterol (r = 0.518, p = 0.005), daytime systolic blood pressure (r = 0.422, p = 0.025), pulse pressure 24 h and daytime (r = 0.424, p = 0.027 and r = 0.449, p = 0.019), early mitral flow/atrial mitral flow (E/A) (r = −0.429, p = 0.023), and posterior wall diameter (PWD) (r = 0.417, p = 0.270). Conclusion In a relatively nonobese group of patients, no significant differences were found in the intima-media thickness between OSA patients without concomitant cardiovascular diseases and healthy controls. This may lead to the conclusion that IMT does not reflect increased risk of cardiovascular events in patients with isolated OSA.